"Mesalamine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed)
| Descriptor ID |
D019804
|
| MeSH Number(s) |
D02.241.223.100.050.300.500 D02.241.223.100.300.595.100.540 D02.241.511.390.595.100.540 D02.455.426.559.389.127.020.452.750 D02.455.426.559.389.127.281.595.100.540 D02.455.426.559.389.657.410.595.100.540
|
| Concept/Terms |
Mesalamine- Mesalamine
- Mesalazine
- m-Aminosalicylic Acid
- m Aminosalicylic Acid
- 5-Aminosalicylic Acid
- 5 Aminosalicylic Acid
- meta-Aminosalicylic Acid
- meta Aminosalicylic Acid
|
Below are MeSH descriptors whose meaning is more general than "Mesalamine".
Below are MeSH descriptors whose meaning is more specific than "Mesalamine".
This graph shows the total number of publications written about "Mesalamine" by people in this website by year, and whether "Mesalamine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 2 | 0 | 2 |
| 2007 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2011 | 1 | 0 | 1 |
| 2018 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Mesalamine" by people in Profiles.
-
Minacapelli CD, Bajpai M, Geng X, Van Gurp J, Poplin E, Amenta PS, Brant SR, Das KM. miR-206 as a Biomarker for Response to Mesalamine Treatment in Ulcerative Colitis. Inflamm Bowel Dis. 2019 01 01; 25(1):78-84.
-
Bajpai M, Seril DN, Van Gurp J, Geng X, Alvarez J, Minacapelli CD, Gorin S, Das KK, Poplin E, Cheng J, Amenta PS, Das KM. Effect of Long-Term Mesalamine Therapy on Cancer-Associated Gene Expression in Colonic Mucosa of Patients with Ulcerative Colitis. Dig Dis Sci. 2019 03; 64(3):740-750.
-
Tursi A, Joseph RE, Streck P. Expanding applications: the potential usage of 5-aminosalicylic acid in diverticular disease. Dig Dis Sci. 2011 Nov; 56(11):3112-21.
-
Kamm MA, Lichtenstein GR, Sandborn WJ, Schreiber S, Lees K, Barrett K, Joseph R. Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis. Inflamm Bowel Dis. 2009 Jan; 15(1):1-8.
-
Lichtenstein GR, Kamm MA, Boddu P, Gubergrits N, Lyne A, Butler T, Lees K, Joseph RE, Sandborn WJ. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol. 2007 Jan; 5(1):95-102.
-
Kamm MA, Sandborn WJ, Gassull M, Schreiber S, Jackowski L, Butler T, Lyne A, Stephenson D, Palmen M, Joseph RE. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology. 2007 Jan; 132(1):66-75; quiz 432-3.
-
Kung SJ, Choudhary C, McGeady SJ, Cohn JR. Lack of cross-reactivity between 5-aminosalicylic acid-based drugs: a case report and review of the literature. Ann Allergy Asthma Immunol. 2006 Sep; 97(3):284-7.
-
Chatzinoff M, Guarino JM, Corson SL, Batzer FR, Friedman LS. Sulfasalazine-induced abnormal sperm penetration assay reversed on changing to 5-aminosalicylic acid enemas. Dig Dis Sci. 1988 Jan; 33(1):108-10.